Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects

Details

Instance of

clinical trial

Start time

1 December 2018

End time

10 November 2022

Country

France, United Kingdom, United States

Main subject

acute graft versus host disease

clinical trial phase

phase I clinical trial, phase II clinical trial

maximum age

17

number of participants

150

research intervention

prednisolone acetate, prednisolone hemisuccinate, prednisolone 21-phosphate, prednisone, methylprednisolone, methylprednisolone acetate, methylprednisolone hemisuccinate, prednisolone

research site

City of Hope National Medical Center, Miami Children's Hospital, Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Center, Bristol Royal Hospital for Children, University of Minnesota, Duke University Medical Center, Vanderbilt University Medical Center, Bambino Gesù Hospital, Strasbourg University Hospital, Leeds Teaching Hospitals NHS Trust

study type

interventional study

title

An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Combination With Corticosteroids for the Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Pediatric Subjects